How Has the Liver Metastases Treatment Market Size Evolved in Recent Years?
The liver metastases treatment market has seen considerable growth due to a variety of factors.
• The liver metastases treatment market has shown strong growth recently. It will grow from $1.57 billion in 2024 to $1.71 billion in 2025, at a CAGR of 8.9%.
The growth can be attributed to the expansion of personalized medicine, broader access to healthcare, improved multidisciplinary care, and increased clinical trials and research.
What Is The Forecast For The Liver Metastases Treatment Market Size?
The liver metastases treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The liver metastases treatment market is expected to see strong growth, reaching $2.37 billion by 2029, growing at a CAGR of 8.5%.
This growth is attributed to the shift toward patient-centric care models, the increasing use of precision medicine, regulatory initiatives, and a growing focus on outpatient and ambulatory care. Key trends include next-generation sequencing technologies, advancements in immuno-oncology, the emergence of liquid biopsy technologies, and adjuvant therapies.
What Are The Essential Drivers Behind The Growth Of The Liver Metastases Treatment Market?
The increasing cases of liver disease are expected to drive the liver metastases treatment market. Liver diseases, including liver cancer, are growing due to factors such as alcohol use, viral infections, and obesity. Treatment for liver metastases includes surgery, ablation, and chemotherapy. Cancer Australia reported that 2,905 new cases of liver cancer were diagnosed in 2022. As a result, the rising number of liver disease cases is propelling the liver metastases treatment market.
How Is The Global Liver Metastases Treatment Market Divided Into Key Segments?
The liver metastases treatment market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Primary Cancer: Colorectal Cancer, Breast Cancer
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Chemotherapy: Cytotoxic Chemotherapy, Neoadjuvant Chemotherapy, Adjuvant Chemotherapy
2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, MTOR Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer Therapy
Pre-Book The Liver Metastases Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Liver Metastases Treatment Industry?
Key players in the liver metastases treatment market are concentrating on developing liver-targeted therapies to provide efficient and convenient treatments. Liver-targeted therapies are drugs or measures that focus directly on illnesses or issues impacting the liver. They address liver metastases by specifically tackling cancer cells in the liver, either by eradicating them directly or obstructing their blood supply, through techniques including surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, and stereotactic body radiation therapy. For example, in August 2023, Delcath Systems Incorporated, a company specializing in interventional oncology based in the US, introduced the Hepzato kit. This liver-targeted treatment is for adult patients with metastatic uveal melanoma (mUM) with inoperable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or a slight extrahepatic disease that is receptive to resection or radiation. Hepzato kit is a combination treatment that delivers melphalan, a chemotherapy drug, directly to the liver via Delcath's Hepatic Delivery System (HDS), enhancing drug exposure in the target organs while curbing systemic toxicity.
Who Are the Key Players In The Liver Metastases Treatment Market?
Major companies operating in the liver metastases treatment market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Merck & Co.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Novartis AG
• Bristol Myers Squibb
• AstraZeneca plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Gilead Sciences Inc.
• Takeda Pharmaceutical Company
• Astellas Pharma Inc.
• Daiichi Sankyo Company Ltd.
• Eisai Co. Ltd.Incyte Corporation
• Ipsen
• Seattle Genetics
• Exelixis Inc.
• Array BioPharma Inc.
• Genentech Inc.
• Clovis Oncology
• Agios Pharmaceuticals Inc.
• Taiho Pharmaceutical Co.Ltd
What Are The Regional Insights Into The Liver Metastases Treatment Market?
North America was the largest region in the liver metastases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver metastases treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
